Why tapping the value generated for the next set of therapies is critical.
Irfan Qureshi, MD
Advertisement
Chief Medical Officer at Biohaven Ltd.
Articles by Irfan Qureshi, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Bring Weight-Loss Medications to TrumpRx
2
Texas Files to Prevent Kenvue Dividend Payment
3
Novo Nordisk Sends Amended Acquisition Proposal to Metsera
4
Pharmaceutical Executive Daily: Kimberly-Clark’s $48.7 Billion Acquisition of Kenvue
5
